Tudor Investment Corp ET AL Has $5.24 Million Stock Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Tudor Investment Corp ET AL increased its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 16.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 267,899 shares of the company's stock after acquiring an additional 37,904 shares during the period. Tudor Investment Corp ET AL owned about 0.22% of Privia Health Group worth $5,237,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Quadrant Capital Group LLC increased its stake in shares of Privia Health Group by 11.8% in the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock valued at $95,000 after acquiring an additional 511 shares during the last quarter. Park Avenue Securities LLC grew its holdings in Privia Health Group by 3.8% during the fourth quarter. Park Avenue Securities LLC now owns 14,697 shares of the company's stock valued at $287,000 after purchasing an additional 532 shares during the period. PNC Financial Services Group Inc. increased its stake in Privia Health Group by 8.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,169 shares of the company's stock valued at $140,000 after purchasing an additional 533 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in Privia Health Group by 53.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after purchasing an additional 632 shares during the period. Finally, Summit Investment Advisors Inc. boosted its position in shares of Privia Health Group by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 10,673 shares of the company's stock worth $209,000 after purchasing an additional 678 shares in the last quarter. 94.48% of the stock is owned by institutional investors.

Insider Transactions at Privia Health Group

In other Privia Health Group news, Director Matthew Shawn Morris sold 10,309 shares of the firm's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $240,508.97. Following the completion of the sale, the director now owns 59,792 shares of the company's stock, valued at $1,394,947.36. This trade represents a 14.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO David Mountcastle sold 3,445 shares of Privia Health Group stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $80,371.85. Following the transaction, the chief financial officer now directly owns 176,231 shares of the company's stock, valued at approximately $4,111,469.23. This trade represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,484 shares of company stock worth $799,163 in the last ninety days. Insiders own 10.70% of the company's stock.

Privia Health Group Stock Performance

PRVA traded up $0.42 during trading on Friday, reaching $23.32. 369,530 shares of the stock were exchanged, compared to its average volume of 770,831. The stock's 50 day moving average price is $23.50 and its two-hundred day moving average price is $22.10. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $26.04. The stock has a market cap of $2.83 billion, a P/E ratio of 233.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.88.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, February 28th. JMP Securities reiterated a "market outperform" rating and issued a $29.00 price objective on shares of Privia Health Group in a research report on Monday, April 28th. Robert W. Baird raised their target price on shares of Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a report on Tuesday, April 15th. Piper Sandler lifted their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, Barclays increased their price objective on shares of Privia Health Group from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Privia Health Group has a consensus rating of "Buy" and a consensus price target of $27.38.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.